GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Revenue

APLM (Apollomics) Revenue : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Revenue?

Apollomics's revenue for the six months ended in Jun. 2024 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil. Apollomics's Revenue per Share for the six months ended in Jun. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Apollomics Revenue Historical Data

The historical data trend for Apollomics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Revenue Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Revenue
- - - -

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of Apollomics's Revenue

For the Biotechnology subindustry, Apollomics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollomics's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's Revenue distribution charts can be found below:

* The bar in red indicates where Apollomics's Revenue falls into.



Apollomics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollomics  (NAS:APLM) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Apollomics Revenue Related Terms

Thank you for viewing the detailed overview of Apollomics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollomics Business Description

Traded in Other Exchanges
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.